We are currently updating our guideline on Dementia: supporting people with dementia and their carers in health and social care (CG42). This update will incorporate the technology appraisal (TA) on Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (TA217).
It has been agreed to separately update the first and third bullets of recommendation 1.3 of the TA
The updated sections of the recommendation will be published separately as an addendum to TA217. When the full update of CG42 is produced, this addendum will then be incorporated into the guideline.